靶向Trop-2抗体药物偶联物在乳腺癌治疗中的研究进展  

Advances of Antibody-Drug Conjugates Targeting Trop-2 in the Treatment of Breast Cancer

作　　者：卢蓉蓉 瞿菲 刘谦 李薇[1] LU Rongrong;QU Fei;LIU Qian;LI Wei(Department of Oncology,the First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院/江苏省人民医院肿瘤科,江苏南京210029

出　　处：《药学进展》2024年第2期118-124,共7页Progress in Pharmaceutical Sciences

摘　　要：滋养层细胞表面抗原2(Trop-2)在正常组织中低表达,在多种肿瘤组织中高表达,且在肿瘤的发生、发展及转移中发挥重要作用。鉴于靶向Trop-2抗体药物偶联物(ADC)戈沙妥珠单抗在晚期三阴性乳腺癌治疗中取得显著突破并获批适应证,以及近期多项靶向Trop-2 ADC大型Ⅲ期临床试验的阳性结果公布,可见研发靶向Trop-2的ADC成为具有前景的肿瘤治疗新策略。概述Trop-2的结构和功能,综述近年来靶向Trop-2 ADC药物治疗乳腺癌的临床研究进展及存在的挑战,以期为乳腺癌患者治疗的选择提供参考。Trophoblast cell surface antigen 2(Trop-2)exhibits underexpression in normal tissue,yet overexpression in many tumor tissues.The overexpression of Trop-2 plays a significant role in the initiation,progression,and metastasis of tumor.With the significant breakthrough of sacituzumab govitecan,anti-Trop-2 antibody-drug conjugate(ADC),in treating advanced triple-negative breast cancer,along with its approved indications and the recent positive findings from various phase III clinical trials regarding ADC targeting Trop-2,the development of ADC targeting Trop-2 has become a promising new strategy for tumor treatment.This review provides a comprehensive overview of the structure and function of Trop-2,the recent advances in clinical research regarding ADC targeting Trop-2 for breast cancer and the existing challenges,aiming to offer some valuable insight for the selection of therapeutic strategies for breast cancer patients.

关 键 词：滋养层细胞表面抗原2 抗体偶联药物 乳腺癌 药物治疗 

分 类 号：R730.51[医药卫生—肿瘤] R737.9[医药卫生—临床医学]